RNA Manufacturing Resources

  1. Genomic Medicine Demands Manufacturing Innovation 5/28/2024

    The promise of novel therapeutic modalities can only be realized when effective science is paired with efficient manufacturing to provide cost-effective therapies to patients in need.

  2. Manufacturing Challenges With High Concentration Biologics 3/18/2024

    Explore key process operations, some of the challenges in manufacturing high-concentration biologics, and factors to consider for process optimization.

  3. Navigating Challenges In Progressing Breakthrough RNA Therapeutics 5/14/2024

    RNA therapeutics hold immense promise for precision treatment, but their development faces challenges. A CDMO with adaptable platforms and flexible timelines can help reduce time and costs.

  4. TFF Cassettes With 100 kDa Membranes For RNA And LNP Applications 7/3/2024

    This study showcases the performance of regenerated cellulose flat sheet membranes with a 100 kDa molecular weight cutoff for UF/DF of RNA molecules by TFF.

  5. Modeling The Economics Of Vaccine Manufacturing 5/26/2023

    Here, we describe the use of a custom-designed cost model to explore the economics of vaccine manufacturing when using different modalities.

  6. mRNA Purification Using Anion Exchange Chromatography At Ambient Temperature 12/11/2024

    Explore how anion exchange chromatography with dual gradient elution enables efficient mRNA purification at ambient temperature.

  7. Exosome Isolation By TFF And Size Exclusion Chromatography 3/6/2024

    Here, we demonstrate a scalable workflow for the isolation of exosomes that combines tangential flow filtration for the concentration of exosomes followed by gentle size exclusion chromatography.

  8. The Value Of Premium Gibco Peptones 5/10/2024

    Achieve the optimal nutritional balance with diverse supplements tailored for your specific bioprocess that can be added to maintain a nutritionally balanced medium.

  9. A Risk-Based Approach To Plasmid DNA And mRNA Process Development 9/23/2025

    Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.

  10. Lipid Nanoparticle Development, Manufacturing Advance Novel Therapeutics 3/22/2022

    An effective partner must possess the necessary unique analytical capabilities for LNP characterization and the ability to support clients from concept to commercialization.